EZH2 and small cell lung carcinoma: However, we found that PROTAC EZH2 degrader-1 did not improve the sensitivity of SCLC to the small molecule multitargeted anlotinib, showing that PROTAC EZH2 degrader-1 could only overcome the resistance of H128 cells to chemotherapeutic drugs.